These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33515019)

  • 1. Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).
    Wefel JS; Armstrong TS; Pugh SL; Gilbert MR; Wendland MM; Brachman DG; Roof KS; Brown PD; Crocker IR; Robins HI; Hunter G; Won M; Mehta MP
    Neuro Oncol; 2021 Jul; 23(7):1125-1138. PubMed ID: 33515019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
    Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
    J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.
    Hall WA; Pugh SL; Wefel JS; Armstrong TS; Gilbert MR; Brachman DG; Werner-Wasik M; Wendland MM; Brown PD; Chao ST; Roof KS; Robins HI; Mehta MP; Curran WJ; Movsas B
    Neurosurgery; 2019 Jan; 84(1):66-76. PubMed ID: 29618054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
    Wefel JS; Cloughesy T; Zazzali JL; Zheng M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Das A; Friedman HS
    Neuro Oncol; 2011 Jun; 13(6):660-8. PubMed ID: 21558074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; King MT; Simes J; Espinoza D; Barnes EH; Sawkins K; Rosenthal MA; Cher L; Hovey E; Wheeler H; Nowak AK
    J Neurooncol; 2017 Jul; 133(3):623-631. PubMed ID: 28534153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.
    Wirsching HG; Tabatabai G; Roelcke U; Hottinger AF; Jörger F; Schmid A; Plasswilm L; Schrimpf D; Mancao C; Capper D; Conen K; Hundsberger T; Caparrotti F; von Moos R; Riklin C; Felsberg J; Roth P; Jones DTW; Pfister S; Rushing EJ; Abrey L; Reifenberger G; Held L; von Deimling A; Ochsenbein A; Weller M
    Ann Oncol; 2018 Jun; 29(6):1423-1430. PubMed ID: 29648580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial.
    Field KM; Barnes EH; Sim HW; Nowak AK; Simes J; Rosenthal MA; Wheeler H; Hovey EJ; Cher LM
    J Clin Neurosci; 2021 Dec; 94():321-327. PubMed ID: 34863458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
    Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
    J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
    Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
    J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Caramanna I; Bottomley A; Drijver AJ; Twisk J; van den Bent M; Idbaih A; Wick W; Pe M; Klein M; Reijneveld JC;
    Eur J Cancer; 2021 Feb; 144():162-168. PubMed ID: 33348088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
    Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma.
    Almahariq MF; Quinn TJ; Arden JD; Roskos PT; Wilson GD; Marples B; Grills IS; Chen PY; Krauss DJ; Chinnaiyan P; Dilworth JT
    Neuro Oncol; 2021 Mar; 23(3):447-456. PubMed ID: 32658268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.
    Li J; Bentzen SM; Li J; Renschler M; Mehta MP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):64-70. PubMed ID: 18406884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current role of anti-angiogenic strategies for glioblastoma.
    Thomas AA; Omuro A
    Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.
    Puduvalli VK; Wu J; Yuan Y; Armstrong TS; Vera E; Wu J; Xu J; Giglio P; Colman H; Walbert T; Raizer J; Groves MD; Tran D; Iwamoto F; Avgeropoulos N; Paleologos N; Fink K; Peereboom D; Chamberlain M; Merrell R; Penas Prado M; Yung WKA; Gilbert MR
    Neuro Oncol; 2020 Oct; 22(10):1505-1515. PubMed ID: 32166308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of volume of irradiation on survival and quality of life in glioblastoma: a prospective, phase 2, randomized comparison of RTOG and MDACC protocols.
    Kumar N; Kumar R; Sharma SC; Mukherjee A; Khandelwal N; Tripathi M; Miriyala R; Oinam AS; Madan R; Yadav BS; Khosla D; Kapoor R
    Neurooncol Pract; 2020 Jan; 7(1):86-93. PubMed ID: 32257287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.